



Management

Raymond J Hohl, MD, PhD
President & Chief Executive Officer

Board of Directors

Stephen Collins, MD, PhD
Chairman

Raymond J Hohl, MD, PhD
President & Chief Executive Officer

David F Wiemer, PhD
University of Iowa

Mark Drish
Iowa First Capital

Overview

Terpenoid Therapeutics, Inc. is a privately-held biotechnology company focused on anti-cancer therapeutics. We use the platform of terpene chemistry to develop candidate drug molecules. Our team is creating, testing, and developing novel drug candidates using cutting-edge technologies. We seek to generate a robust pipeline of terpene-derived therapeutic agents.

Two projects are in advanced preclinical testing with lead compounds identified in both projects. One project is focused on development of small molecule inhibitors of geranylgeranyl diphosphate synthase, a novel target with applicability towards cancer and other indications. Another project is focused on development of the schweinfurthins, a family of novel anti-cancer agents that disrupt cholesterol metabolism.

Terpenoid projects are built upon a fifteen-year academic collaboration of the Terpenoid founders who have expertise in the biology and chemistry of terpene metabolism, pharmacology and oncology. The company is located in the University of Iowa BioVentures Center in Coralville, IA. The company maintains active collaborations with the academic labs of the founders.

We are working to build a successful drug discovery and development company that is capable of commercializing first-in-class drugs. We hope the compounds we bring to market can contribute to a better quality of life for patients suffering with cancer.

Technology

Bisphosphonates

Terpenoid's bisphosphonate project is based on proprietary terpenoid-modified bisphosphonate inhibitors of geranylgeranyl diphosphate synthase (GGDPS), a novel target for which there is no approved drug at this time. Terpenoid predicts that inhibition of GGDPS will result in efficacy in the treatment of primary tumors and metastases (including, but not limited to, bone metastases).

Schweinfurthins

Terpenoid's schweinfurthin project is focused on developing a drug with activity against primary tumors and metastases. This project is based on disruption of cholesterol metabolism by rare schweinfurthin natural products whose unique profile of anti-cancer activity was first reported by the National Cancer Institute in 1998.